🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

403 results for “Institut für biomedizinische Analytik NMR-Imaging GmbH” Clear

  1. A Phase I First-in-Human Dose Escalation Trial to Evaluate the Safety and Efficacy of ARI-HER2 (HER2BBz CAR-T Cells) in Patients with HER2Positive Advanced Breast Cancer

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients with HER2Positive Advanced Breast Cancer

    phase 2 other active

    1 trial

  2. A phase I study evaluating safety and efficacy of Hepatic Intra- Arterial administration of ipilimumab in combination with Intra- venous nivolumab for advanced Hepatocellular carcinoma (HIPANIV)

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Advanced hepatocellular carcinoma

    phase 2 other active

    1 trial

  3. A phase II, monocentric, single arm trial evaluating the efficacy and safety of Pembrolizumab in combination with Lenvatinib in metastatic Uveal MElanoma patients

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Metastatic uveal melanoma

    phase 2 other active

    1 trial

  4. ABTL0812, IRINOTECAN, TEMOZOLOMIDE

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Relapsed/refractory neuroblastoma and other solid tumours

    phase 2 small molecule active

    1 trial

  5. ADMSC-fib safety and efficacy in patients with chronico wounds

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    chronic wounds

    phase 2 other active

    1 trial

  6. AG-120/S95031 250mg film-coated tablet, IMFINZI 50 mg/mL concentrate for solution for infusion., Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation

    phase 2 small molecule active

    1 trial

  7. ALDESLEUKIN , Tumor Intiltrating Lymphocytes (TIL) – VHIO, FLUDARABINE , CYCLOPHOSPHAMIDE

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Germ Cell Tumors refractory to salvage chemotherapy

    phase 2 small molecule active

    1 trial

  8. ARICEPT 10mg comprimidos recubiertos con película

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Parkinson's disease

    phase 2 small molecule active

    1 trial

  9. ASP3082, DEXTROSE INJECTION / BRADEX 5%

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Metastatic Non-small cell lung cancer (NSCLC) and Pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  10. ATEZOLIZUMAB

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients with metastatic tumours (colorectal, non-small cell lung, renal and sarcoma)

    phase 2 small molecule active

    1 trial

  11. AUTOLOGOUS DENDRITIC CELLS LOADED WITH AUTOLOGOUS TUMOR LYSATE, Tecentriq 1 200 mg concentrate for solution for infusion

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Lung Cancer

    phase 2 small molecule active

    1 trial

  12. Abraxane 5 mg/ml powder for dispersion for infusion., IRINOTECAN VIATRIS 20 mg/ml, solution à diluer pour perfusion, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui, OXALIPLATINE ARROW LAB 5 mg/mL, solution à diluer pour perfusion, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, LEVOFOLINATE DE CALCIUM ZENTIVA 25 mg/2,5ml, solution injectable (IM/IV)

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    local advenced pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial

  13. AdaptNK –Cell Therapy for High-risk Myeloid Disease

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Relapsed and/or refractory AML or MDS

    phase 2 other active

    1 trial

  14. Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cells (MSC) ectopically expressing CXCR4 and IL10

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients who have developed acute GVHD refractory to corticosteroids and ruxolitinib or that are not eligible to receive ruxolitinib

    phase 2 small molecule active

    1 trial

  15. AloCelyvir

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    mEtastatic Uveal Melanoma

    phase 2 small molecule active

    1 trial

  16. Alunbrig 30 mg film-coated tablets, CRIZOTINIB, LORLATINIB, Zykadia 150 mg hard capsules, ALECTINIB

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    locally advanced (stage III) and not suitable for curative treatment, or metastatic (stage IV) ALK+ NSCLC, ALK+ NSCLC

    phase 2 small molecule active

    1 trial

  17. Amimox 500 mg filmdragerade tabletter, Kåvepenin 800 mg filmdragerade tabletter

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Need of Oral bone augmentation

    phase 2 small molecule active

    1 trial

  18. BAY 73-4506, AVELUMAB

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Adult patients with advanced or metastatic solid tumors

    phase 2 small molecule active

    1 trial

  19. BI 907828, Ezabenlimab, BI 907828, BI 907828

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Adult patients with locally advanced/metastatic solid tumors

    phase 2 small molecule active

    1 trial

  20. BOOST cells

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Osteogenesis Imperfecta (OI) type III and severe type IV. Severe type of congenital Brittle bone disease.

    phase 2 small molecule active

    1 trial

  21. BOTULINUM TOXIN , -

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Myogenous temporomandibular disorders (TMDM)

    phase 2 small molecule active

    1 trial

  22. Bleomycin medac, 15 000 RÜ süstelahuse pulber

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    VASCULAR MALFORMATION

    phase 2 small molecule active

    1 trial

  23. Busulfan 6 mg/ml concentrate for solution for infusion, THYMOGLOBULINE 5 mg/ml, poudre pour solution pour perfusion, Fludarabine Accord Healthcare 25 mg/ml solution à diluer pour solution injectable /pour perfusion

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    High-risk myeloïd malignancies

    phase 2 small molecule active

    1 trial

  24. Byetta 10 micrograms solution for injection in pre-filled pen

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Hypopituarism

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources